Planet Labs Posts Record Revenue but Stock Slides on $1.5B Equity Offering

What happened

Planet Labs reported Q1 FY2027 revenue of $94.2M, a record 42% YoY increase, and guided FY2027 revenue to $425M-$441M. However, the company also filed a prospectus for a common stock offering of up to $1.5B, which sent shares lower. The DeepValue report notes that while the company has $730.8M in cash and $447.6M in convertible notes, the offering introduces significant dilution risk. The backlog and RPO growth are strong, but the quality of contracts remains a concern due to cancelable and unappropriated components. This equity raise could be necessary to fund Pelican deployment and sovereign contracts, but it undermines the narrative of self-funding growth.

Implication

Long-term investors should scrutinize the use of proceeds and whether dilution is offset by faster growth. The offering may be opportunistic to capitalize on high valuation, but it also raises questions about capital needs beyond the guided capex. Until the offering is completed and use of proceeds clarified, maintain a cautious stance.

Thesis delta

The equity offering introduces a significant dilution event that was not a focus of the previous thesis. While backlog and revenue growth are strong, the offering suggests management sees a need to raise capital, possibly for sovereign contract execution or balance sheet strengthening. This shifts the investment thesis from a wait-and-see on contract quality to a wait-and-see on dilution impact and capital allocation discipline.